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1. Introduction
Traumatic spinal cord injury (SCI) is usually caused by 
excessive forces taking effect on vertebral column. Spinal 
cord tissues are damaged by displaced bone fragments, 
intervertebral discs or ligaments. After contusive injury 
to the spinal cord, pathological changes develop as a 
two-stage process [1,2]. The primary injury is caused 
immediately by mechanical damage to neural tissue 
(including blood vessels), and is followed by secondary 
processes, leading to posttraumatic autodestruction of 
spinal cord tissue [3-5]. The mechanisms of secondary 
injury are not completely understood, but include 
ischemia, biochemical changes and inflammatory 
processes contributing to gradual extension of the 
primary lesion. Histological observations indicate that 
secondary destruction takes place within the course 
of days and even weeks after injury [1,5], and that the 
enlargement of the lesion progresses from the center 
to the periphery of the spinal cord [6]. Progressive 
secondary injury involves gradual destruction of 
the white matter that can play an important role in 
the final functional deficit after SCI [7]. The detailed 
understanding of the molecular processes involved 
in secondary injury is therefore of great importance in 
SCI research. It would enable more specific therapeutic 
interventions aimed at minimizing the tissue loss at the 
injury site.
Studies on the dynamics of the development of 
secondary changes indicate that the major enlargement 
of the primary lesion occurs within the first 24 hours 
after injury. We have therefore proposed that treatments 
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Abstract:  Kynurenic acid (KYNA), a metabolite of the essential amino acid L-tryptophan, is a broad spectrum antagonist of excitatory amino acid 
receptors, which have also anticonvulsant and neuroprotective properties. After spinal cord injury (SCI), excitotoxicity is considered 
to play a significant role in the processes of secondary tissue destruction in both grey and white matter of the spinal cord. In this 
study, we have tested the potential therapeutic effect of glucosamine-kynurenic acid, administered after experimental compression-
induced SCI in the rat. Spinal application of glucosamine-kynurenic acid continually for 24 hr after experimental SCI resulted in 
improved motor function recovery, beginning from the first week of evaluation and continuing until the end of the study (4 weeks). 
After 4 weeks‘ survival, quantitative morphometric analysis of the spinal cord showed that glucosamine-kynurenic acid treatment 
was associated with improved tissue preservation at the lesion site. These findings indicate that spinal application of glucosamine-
kynurenic acid is neuroprotective and improves the outcome even when administered after spinal trauma. Our results suggest 
that the treatments initiated in early posttraumatic period can alleviate secondary injury and improve the final outcome after SCI.
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aimed at diminishing secondary tissue injury should be 
applied during the first 24 hours after trauma [6,8]. 
In animal experiments, several drug treatment 
studies reported promising results [9]. However, almost 
none of them have been found effective in clinical 
settings. So far, only methylprednisolone (MP), a potent 
synthetic glucocorticoid, has been shown effective at 
reducing neurological impairment after acute spinal cord 
trauma in clinical studies [10]. However, controversies 
still exist about its real therapeutic effect. Systemic 
administration of high doses of MP is associated with 
serious side-effects, and its standard use after SCI 
remains a matter of debate [11]. 
Excitatory amino acids (EAA) play an important role 
in the pathomechanisms of secondary injury after SCI. 
After trauma, local concentrations of several amino acids 
are significantly increased [12]. In brain ischemia and 
trauma studies, EAA antagonists have been the most 
potent  neuroprotectants [13,14]. Kynurenic acid (KYNA) 
is an endogeneous intermediate in the tryptophan 
metabolic pathway synthesized via the irreversible 
transamination of its bioprecursor, L-kynurenine by 
kynurenine aminotransferases [15]. It acts by blocking 
the co-agonist glycine site of the N-methyl-D-aspartate 
(NMDA) receptor [16], thereby limiting neurotoxicity 
resulting from NMDA receptor overstimulation [17]. In 
addition, KYNA behaves as a noncompetitive inhibitor of 
the α-7 nicotinic acetylcholine receptor [18] and a ligand 
for GPR35 localized mainly in gastrointestinal tract and 
immune cells [19]. These observations indicate the 
complexity of the neurophysiological actions of KYNA in 
CNS. In a rat SCI study, local application of KYNA before 
and early after trauma has been found neuroprotective 
[20]. The present study has been performed to find out 
whether posttraumatic application of KYNA, which is 
more appropriate for clinical use, will have any effect 
on the outcomes after experimental SCI. We have 
used a KYNA analogue glucosamine-kynurenic acid, 
a derivative developed and synthesized in the Institute 
of Medicinal Chemistry, University of Szeged, Hungary 
in order to improve the blood-brain barrier transport of 
KYNA [21,22]. 
2. Experimental Procedures 
2.1 Experimental animals
A total of 30 male adult Wistar rats weighing from 300 
to 330 g were used in this experiment. All surgical 
procedures were performed in accordance with the 
European Communities Council Directive (86/906/EEC) 
regarding the use of animals in research, and Slovak 
Law for Animal Protection No. 115/1995.
2.2  Intrathecal catheter implantation and 
compression spinal cord injury
Intrathecal catheter was implanted to all experimental 
animals 24 hours prior to spinal cord injury. Briefly, under 
halothane anesthesia (1.5-2% by facial mask), a PE-5 
(4-cm long) sterile polyethylene catheter was introduced 
through the incision in the atlanto-occipital membrane, 
threaded down to the Th7-Th8 level of spinal cord, fixed 
in place by suturing it to the neck superficial muscles 
and sealed until the time of drug delivery to prevent 
infection and leakage of cerebrospinal fluid. 
Twenty-four hours after the catheter was implanted, 
animals were evaluated for any motor abnormalities. 
Only intact animals with normal motor behaviour 
were included in the study and re-anesthetized. 
A laminectomy was performed to expose the spinal 
cord at Th9-10, and SCI was induced by epidural 
balloon inflation using the method described by Vanicky 
et al.  [23]. Briefly, a 2-French Fogarty catheter (Baxter 
Healthcare Corporation, Irvine, CA) was inserted via 
a small hole (1.5 mm diameter) in the Th10 vertebral 
arch into the epidural space and moved cranially up for 
1 cm, with the centre of the balloon at the Th8-9 level. 
After stabilization of the body temperature at 37°C, the 
Fogarty catheter linked to a 50 μl Hamilton syringe (type 
1705) was rapidly inflated with 12.5 μl of distilled water 
for 5 min. Thereafter, the catheter was deflated, removed 
from epidural space, and the soft tissues and skin were 
sutured in anatomical layers. The animals were housed 
individually. Their bladders were expressed manually 
twice a day for the duration of the study (28 days) or 
until the recovery of spontaneous micturition, typically in 
the second week postoperatively.
2.3 Pharmacological treatment
The new analogue of KYNA (glucosamine-kynurenic 
acid) was dissolved in 0.1 M sodium hydroxide, and pH 
of the solution was adjusted to 7.4 with HCl for the final 
concentration of 50 mM. Immediately after injury, spinal 
catheters were connected via a long tubing to a syringe 
pump. The tubing was suspended on a balance arm 
to allow continuous spinal application of the fluid to 
freely moving animals (Figure 1). Rats were randomly 
assigned into two groups receiving either glucosamine-
kynurenic acid (n=15) or saline (control group, n=15) 
continually for 24 h at delivery rate 5 μl/h. The total dose 
od glucosamine-kynurenic acid delivered during 24 h 
was 60 μmol.
2.4 Evaluation of locomotor recovery
The locomotion of experimental animals was first 
assessed 24 hours after injury (day 1) and then weekly 
during the whole survival period. Animals were placed 
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in an open field and their spontaneous locomotion was 
assessed by two observers. Hindlimb movements were 
evaluated according to the Basso-Beattie-Bresnahan 
(BBB) scale from 0 to 21 points (from no observable 
locomotor movements to normal locomotor activity). 
This scale categorizes combinations of hindlimb 
joint movements, walking pattern, coordination, 
trunk stability, paw placement and tail position and 
stability [24]. As a measure of overall health in both 
experimental groups, body weights were periodically 
recorded in the same time intervals as the locomotor 
recovery tests.
2.5  Histological and morphometric analysis of 
spared spinal cord tissue
After 4 weeks, rats were deeply anesthetized 
by intraperitoneal injection of ketamine/xylazine 
(0.6 ml/0.3 ml) and perfused transcardially with 
0.9% cold physiological saline followed by 4% cold 
paraformaldehyde in 0.1 M phosphate buffer (pH 
7.4). The spinal cords were carefully dissected from 
the vertebral canal and postfixed by immersion in 
the same fixative for 24 hours. Dura mater was 
carefully removed and spinal cords were embedded 
in a glutaraldehyde-polymerised protein matrix as 
reported by Herzog and Brosamle [25] in order to 
facilitate systematic sampling. Consequently, a 3 cm 
long piece of the spinal cord (containing the lesion 
at its center) was cut trasversally with aid of metallic 
matrix into 1mm thick blocks. The blocks marked for 
proper orientation were flat-embedded in paraffin 
and 5 μm thick sections were cut from the surface 
of each block. A resulting series of 30 consecutive 
sections at 1 mm distances was stained with Luxol 
Fast Blue/Cresyl Violet. High-resolution images were 
used to delineate the areas of the preserved tissue. 
Scar tissue around the cavities and tissues with 
abnormal architecture were excluded. The cross-
sectional areas of the white and grey matter were 
measured using image analysis software (Image Tool 
for Windows 2.00). From a series of cross-sectional 
areas, the volume of the spared tissue was calculated. 
Craniocaudal length of the lesion was measured as a 
separate morphometric parameter.  
2.6 Statistical analysis
BBB scores were averaged across hindlimbs to get 
a single score per animal. Intergroup differences at 
different times after injury were compared statistically 
using repeated-measures ANOVA, followed by Tukey´s 
test. Body weight measurements at individual survival 
time points were compared by the unpaired Student’s 
t-test. For comparison of cross-sectional areas of 
spared tissue, 27 lesion-centered sections were used. 
Intergroup differences were evaluated separately for the 
white matter and grey matter, using repeated-measures 
ANOVA, followed by Tukey´s test. The volume of the 
preserved tissue in this 27 mm long segment was 
calculated as a sum of cross-sectional areas multiplied 
by the distance between them. Intergroup differences 
were analyzed with unpaired Student’s t-test. 
All values were expressed as means±S.E.M. 
Differences between groups were considered 
statistically significant if P<0.05.
Figure 1. Illustration demonstrating intrathecal drug delivery setup via syringe pump after compression-induced SCI.
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3. Results
3.1 Body weight changes
The body weight recordings in both experimental groups 
are shown in Figure 2. After injury, there was a rapid loss 
in body weight, followed by gradual recovery during the 
survival period. No significant differences were found 
between the treatment and placebo groups.
3.2  Effect of glucosamine-kynurenic acid on 
locomotor activity after SCI
Immediately after injury, animals in both groups had 
a complete paralysis of their hindlimbs. During the four 
weeks‘ survival period all animals exhibited gradual 
recovery of their hindlimb movements. By the 7th day 
post-injury, animals treated with glucosamine-kynurenic 
acid demonstrated better recovery of motor functions 
compared to placebo group. The BBB scores were 
approximately 2 points higher than those in the saline-
treated group. These intergroup differences were also 
observed on days 14, 21 and 28 after injury, and at all 
these time points the differences reached statistical 
significance (P<0.05). After 4 weeks post-injury, 
glucosamine-kynurenic acid treated rats reached BBB 
score of 14.7±1.5, whereas the BBB rating scale for 
control group was 12.5±1.3 (Figure 3). 
Figure 2. Body weights measured at individual time points (T/IT - trauma/intrathecal drug delivery).
Figure 3.  Open field locomotion test. Repeated BBB scores achieved during 28 days‘ survival period. The rats receiving glucosamine-kynurenic 
acid exhibited a significant improvement in hindlimb locomotor function compared with the saline control group. Data were analysed 
with repeated-measures ANOVA which showed an overall significant (P<0.05) effect of treatment. Asterisks indicate that means are 
significantly different from control group at the specified times after compression-induced SCI (T/IT - trauma/ intrathecal drug delivery).
999
Brought to you by | University of Szeged
Authenticated
Download Date | 10/26/16 1:57 PM
Protective effects of glucosamine-kynurenic acid 
after compression-induced spinal cord injury in the rat
3.3  Effect of glucosamine-kynurenic acid on 
the lesion size
To evaluate the effects of glucosamine-kynurenic acid 
on the extent of spinal cord tissue damage, complex 
morphometric analyses of the lesion were performed. 
A series of cross-sectional areas indicated that generally, 
there was more tissue preserved in glucosamine-
kynurenic acid treated group. This tendency was 
more pronounced in grey matter, and at some levels, 
these differences reached statistical significance 
(Figure 4A,B). Total volume calculations also indicated 
better tissue preservation in the glucosamine-kynurenic 
acid treated group, but the differences were not 
statistically significant (Figure 5). The average length 
of the lesion in control animals was 30.1±2.1 mm. In 
glucosamine-kynurenic acid treated animals the lesion 
length was reduced to 27.7±1.5 mm, but this difference 
did not reach statistical significance.
Figure 4.  Tissue sparing as assessed by analyzing the cross-sectional areas of spinal cords removed from glucosamine-kynurenic acid and 
saline treated group after 4 weeks. (A) Grey matter areas in spinal cord sections caudal (-1 to -13 mm) and rostral (1 to 13 mm) to 
the lesion epicenter. (B) White matter areas at the epicenter and in sections caudal and rostral to the epicenter. Repeated-measures 
ANOVA indicated  an overall significant differences in grey and white matter area between the glucosamine-kynurenic acid treated and 
the control group, with significant differences at specified distances to the epicenter (*P<0.05, **P<0.01).
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4. Discussion
As early as 15 min after SCI, extracellular EAA 
concentrations can rise to the levels that are apparently 
toxic to neurons [26,27]. It has been proposed that 
the increase in extracellular EAAs after traumatic SCI 
allows excessive Ca2+ and water influx into the neurons 
mainly via the NMDA receptors, resulting in cellular 
edema and neuronal death [28]. Thus, overactivation 
of EAA receptors is considered to be one of the major 
contributors to the pathophysiological cascade leading 
to tissue destruction after traumatic SCI [29], and 
EAA receptor antagonists have been the most potent 
neuroprotectants in experimental SCI treatment studies. 
In the present study we have tested the 
neuroprotective effects of a glucosamine-kynurenic 
acid on the functional outcome and spinal lesion size 
after standardized SCI in the rat. KYNA is the only 
known endogeneous NMDA receptor inhibitor and thus 
represents a potential therapeutic agent in various 
neurodegenerative diseases where excitotoxicity is 
considered to play a role in pathophysiological cascade. 
However, KYNA has a limited ability to cross the blood-
brain barrier. A new KYNA analogue, glucosamine-
kynurenic acid has been synthesized in the Institute of 
Medicinal Chemistry, University of Szeged, Hungary, 
with the aim to prepare a drug that would cross the 
blood-brain barrier better than KYNA, while maintaining 
its effects on CNS when applied either peripherally or 
directly into the CNS [21,30].  
The aim of this treatment study was twofold: 
1, to test the neuroprotective effects of the new KYNA 
analogue after CNS trauma, and 2, to determine 
whether a clinically relevant administration (continual 
spinal infusion during 24 hours after injury) can influence 
the long-term consequences of SCI. We have used the 
balloon-compression technique of SCI, representing 
a highly reliable and reproducible SCI model [23], 
associated with the interruption of the major long spinal 
tracts (dorsal funiculi, pyramidal tracts) at the injury 
epicenter. 
The results of our experiments have shown that 
intrathecal infusion of glucosamine-kynurenic acid 
is a safe technique of long-term drug application. In 
glucosamine-kynurenic acid treated animals we have 
observed a modest but significant improvement in 
locomotor recovery (~2 points in BBB score) detected 
first after 7 days and then persisting throughout the 
whole survival period. Morphometric data indicated 
overall improvement in perilesional tissue preservation 
in the glucosamine-kynurenic acid treated group. The 
improved tissue preservation was more pronounced in 
the grey matter, but also in the white matter, there was 
more preserved tissue almost at all levels throughout 
the lesion. At some points these differences reached 
statistical significance. In addition, both total volume 
of the spared tissue calculations and craniocaudal 
length of the lesion indicated improved outcomes in 
glucosamine-kynurenic acid treated animals although 
these differences did not reach statistical significance.
Our findings are consistent with earlier observations 
that peri-traumatic EAA receptor blockade after 
experimental SCI can improve functional deficits 
caused by injury [20,31,32].  It has been demonstrated 
that experimental CNS traumatic injury is associated 
with several-fold increase in extracellular EAAs, 
especially glutamate and aspartate [12,26,33]. This 
increase in extracellular concentrations is caused by 
Figure 5.  Calculated volumes of the spared tissue in the analysed spinal cord segments (27 mm) in glucosamine-kynurenic acid and saline 
treated group. No significant treatment effect was seen. Data are represented as group means ±SEM.
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a combination of impaired glutamate reuptake and 
calcium-dependent glutamate synaptic release. High 
levels of extracellular glutamate concentration are 
toxic to neural cells. Especially in hypoxic conditions, 
ionotropic glutamate receptors, i.e. NMDA and 
AMPA/kainate are overstimulated and can trigger 
the process of excitotoxic neuronal death [34,35]. 
Mechanisms of excitotoxicity are complex, but are 
believed to involve excessive intracellular Ca2+ influx 
associated with mitochondrial injury and impaired 
energy production, triggering a vicious cycle leading 
to cellular edema and lysis [36,37]. This cascade is 
relatively well understood in grey matter. However, 
after SCI, mechanisms leading to secondary white 
matter destruction are even more important. It has 
been long believed that white matter is resistant to 
excitotoxic injury, as it does not contain synapses. 
However, in vitro experiments indicate that under 
anoxic conditions, glutamate levels increase and may 
destroy the white matter structures as well. Prolonged 
exposition of central white matter to increased 
concentrations of glutamate, AMPA and kainate brings 
about irreversible axonal injury mediated primarily via 
non-NMDA receptors [38,39]. These findings were 
supported by in vivo observations documenting that 
antagonists of AMPA receptors reduce the lesion 
size in the epicenter, and improve neurological 
outcomes after SCI [32]. Rosenberg et al. [40] have 
demonstrated that AMPA blockers can reduce the 
amount of injured white matter and oligodendrocyte 
loss after spinal cord traumatic injury. 
In general, the results of our study support the 
importance of EAA receptor blockade in functional 
recovery after spinal cord injury. We have shown that 
continuous local delivery of  glucosamine-kynurenic acid 
via intrathecal catheter after experimental spinal cord 
injury is a safe treatment which can lead to behavioral 
improvements and prevent secondary destruction of 
the spinal tissue. It supports the view that secondary 
processes after spinal trauma mediated via excitotoxic 
mechanisms play an important role in tissue destruction. 
Secondary extension of the lesion is a relatively slow 
process that contributes to the final functional deficit, 
and provide a therapeutic window for specific treatment 
interventions.
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